Roles of FGF19 in Liver Metabolism

被引:99
作者
Kir, S. [1 ]
Kliewer, S. A. [1 ,2 ]
Mangelsdorf, D. J. [1 ,3 ]
机构
[1] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA
[3] Univ Texas Southwestern Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA
来源
METABOLISM AND DISEASE | 2011年 / 76卷
关键词
BILE-ACID SYNTHESIS; HEPATOCELLULAR-CARCINOMA; GLUCOSE-HOMEOSTASIS; RECEPTOR; FIBROBLAST-GROWTH-FACTOR-19; SUPPRESSION; EXPRESSION; KLOTHO; MTORC1; SIGNAL;
D O I
10.1101/sqb.2011.76.010710
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fibroblast growth factor 19 (FGF19) is an ileum-derived postprandial enterokine that governs bile acid and nutrient metabolism. Synthesis of FGF19 is up-regulated by bile acids and, conversely, bile acid synthesis is down-regulated by FGF19. FGF19 also controls gallbladder volume. FGF19 has been shown to have profound effects on glucose and lipid metabolism. Recent studies have described FGF19 as a postprandial regulator of hepatic glucose and protein metabolism. Like insulin, FGF19 induces protein and glycogen synthesis and suppresses gluconeogenesis in liver. However, unlike insulin, FGF19 does not stimulate lipogenesis. A key difference between FGF19 and insulin lies in their use of different cellular signaling pathways. The beneficial effects of FGF19 on liver metabolism raise the question of whether FGF19 and its variants can be used as therapeutic agents in the treatment of diabetes.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 31 条
[1]   The FGF family: biology, pathophysiology and therapy [J].
Beenken, Andrew ;
Mohammadi, Moosa .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) :235-253
[2]   Identification of a hormonal basis for gallbladder filling [J].
Choi, Mihwa ;
Moschetta, Antonio ;
Bookout, Angie L. ;
Peng, Li ;
Umetani, Michihisa ;
Holmstrom, Sam R. ;
Suino-Powell, Kelly ;
Xu, H. Eric ;
Richardson, James A. ;
Gerard, Robert D. ;
Mangelsdorf, David J. ;
Kliewer, Steven A. .
NATURE MEDICINE, 2006, 12 (11) :1253-1255
[3]   Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth [J].
Dong, XC ;
Park, SM ;
Lin, XY ;
Copps, K ;
Yi, XJ ;
White, MF .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :101-114
[4]   Fibroblast growth factor 19 increases metabolic rate I and reverses dietary and leptlin-deficient diabetes [J].
Fu, L ;
John, LM ;
Adams, SH ;
Yu, XX ;
Tomlinson, E ;
Renz, M ;
Williams, PM ;
Soriano, R ;
Corpuz, R ;
Moffat, B ;
Vandlen, R ;
Simmons, L ;
Foster, J ;
Stephan, JP ;
Tsai, SP ;
Stewart, TA .
ENDOCRINOLOGY, 2004, 145 (06) :2594-2603
[5]  
Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695
[6]   eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation [J].
Gingras, AC ;
Raught, B ;
Sonenberg, N .
ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :913-963
[7]   Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention [J].
Ho, Han Kiat ;
Pok, Sharon ;
Streit, Sylvia ;
Ruhe, Jens E. ;
Hart, Stefan ;
Lim, Kah Suan ;
Loo, Hool Linn ;
Aung, Myat Oo ;
Lim, Seng Gee ;
Ullrich, Axel .
JOURNAL OF HEPATOLOGY, 2009, 50 (01) :118-127
[8]   Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis [J].
Holt, JA ;
Luo, GZ ;
Billin, AN ;
Bisi, J ;
McNeill, YY ;
Kozarsky, KF ;
Donahee, M ;
Wang, DY ;
Mansfield, TA ;
Kliewer, SA ;
Goodwin, B ;
Jones, SA .
GENES & DEVELOPMENT, 2003, 17 (13) :1581-1591
[9]   Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis [J].
Inagaki, T ;
Choi, M ;
Moschetta, A ;
Peng, L ;
Cummins, CL ;
McDonald, JG ;
Luo, G ;
Jones, SA ;
Goodwin, B ;
Richardson, JA ;
Gerard, RD ;
Repa, JJ ;
Mangelsdorf, DJ ;
Kliewer, SA .
CELL METABOLISM, 2005, 2 (04) :217-225
[10]   Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho [J].
Ito, S ;
Fujimori, T ;
Furuya, A ;
Satoh, J ;
Nabeshima, Y ;
Nabeshima, Y .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (08) :2202-2208